Physician profile
Matthew W Eidem
NPI 1376650366
$15,301.90
in general payments reported to CMS, 2019-2025
44 companies · $2,692 in 2025
The $2,692 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $994 · 2021: $1,873 · 2022: $2,422 · 2023: $2,313 · 2024: $2,896 · 2025: $2,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,789 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,788.89 |
| Education | $111.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,576.09 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,928.19 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,722.96 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,685.69 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $861.35 | 2019-2025 | |
| Ardelyx, INC. | $459.19 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $364.87 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Celgene Corporation | $318.79 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $301.15 | 2023-2025 | Zenpep, Vowst |
| Mauna Kea Technologies, INC. | $293.98 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $277.68 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $239.37 | 2019-2023 | Clenpiq, Rebyota |
| Lilly USA, LLC | $222.75 | 2024-2025 | Omvoh |
| Medtronic, INC. | $209.18 | 2022-2024 | Pillcam, Gi Genius |
| Genzyme Corporation | $201.61 | 2022-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $183.50 | 2021-2023 | |
| Madrigal Pharmaceuticals | $150.17 | 2025 | Rezdiffra |
| Celltrion USA INC. | $123.10 | 2024-2025 | Vegzelma, Zymfentra |
| Vivus LLC | $117.72 | 2021-2025 | Pancreaze, Qsymia |
| Qol Medical, LLC | $113.79 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $106.67 | 2019-2020 | |
| Braintree Laboratories, INC. | $71.84 | 2019-2024 | Sutab, Suflave |
| Amgen INC. | $69.87 | 2020-2023 | Avsola, Amjevita |
| Phathom Pharmaceuticals, INC. | $65.70 | 2024 | Voquezna |
| Evoke Pharma, INC. | $65.07 | 2022-2024 | Gimoti |
| Fresenius Kabi USA, LLC | $60.01 | 2023-2024 | Idacio |
| Allergan, INC. | $57.62 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $52.17 | 2019-2023 | Linzess |
| Ucb, INC. | $50.23 | 2019-2020 | |
| Axonics, INC. | $48.69 | 2023 | Axonics |
| Ipsen Biopharmaceuticals, INC | $44.98 | 2024-2025 | Iqirvo |
| Endo Pharmaceuticals INC. | $37.89 | 2019 | |
| Enterra Medical, INC. | $28.92 | 2024 | |
| Intercept Pharmaceuticals, INC. | $27.25 | 2020 | |
| Boston Scientific Corporation | $25.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.11 | 2023 | Zeposia |
| Redhill Biopharma INC. | $19.63 | 2020 | |
| Shire North American Group INC | $18.70 | 2019 | |
| Abbott Laboratories | $18.04 | 2019 | |
| Alfasigma USA, INC. | $17.72 | 2020 | |
| Endogastric Solutions, INC | $15.43 | 2024 | Esophyx |
| Micro-Tech Endoscopy USA, INC. | $11.93 | 2020 | |
| Organon LLC | $11.63 | 2023 | Renflexis |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,190.59 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Eidem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.